Achieving sufficient delivery across the blood–brain barrier is a key challenge in the
development of drugs to treat central nervous system (CNS) disorders. This is particularly …

Abstract Development of novel therapies for central nervous system (CNS) disorders has
experienced a high failure rate in clinical trials owing to unsatisfactory efficacy and adverse …

Antiamyloid antibodies have been used to reduce cerebral amyloid-beta (Aβ) load in
patients with Alzheimer's disease. We applied focused ultrasound with each of six monthly …

Focused ultrasound (FUS) is a disruptive medical technology, and its implementation in the
clinic represents the culmination of decades of research. Lying at the convergence of …

The history of brain drug delivery is reviewed beginning with the first demonstration, in 1914,
that a drug for syphilis, salvarsan, did not enter the brain, due to the presence of a blood …

Background Low-intensity pulsed ultrasound with concomitant administration of intravenous
microbubbles (LIPU-MB) can be used to open the blood–brain barrier. We aimed to assess …

The blood-brain barrier (BBB) is a dynamic structure that functions as a gatekeeper,
reflecting the unique requirements of the brain. In this review, following a brief historical …

The blood-brain barrier (BBB) is an important factor limiting the effectiveness of central
nervous system (CNS) therapeutics. MR-guided focused ultrasound (MRgFUS) is a …

The blood brain barrier (BBB) plays a critically important role in the regulation of central
nervous system (CNS) homeostasis, but also represents a major limitation to treatments of …

Therapeutic ultrasound strategies that harness the mechanical activity of cavitation nuclei for
beneficial tissue bio-effects are actively under development. The mechanical oscillations of …